摘要
糖耐量减低(impaired glucose tolerance, IGT)是大部分2型糖尿病(diabetes mellitus type 2,T2DM)的早期现象之一,越来越多的研究发现,IGT人群是预防T2DM的重要干预人群。虽然生活方式的干预可以降低IGT向T2DM的转归,但持续性的生活方式干预不易坚持,并且有部分高危的IGT患者需要药物治疗的介入。目前存在已知的降糖西药,但由于其副作用较大,不良反应较多,更多的患者愿意使用中成药进行治疗。中成药不仅疗效显著,而且通过药物的配伍可以达到增效减毒的作用。本文探讨了糖耐量受损的发病机制,针对临床中干预IGT的中成药,探究了使用频次较高部分单味药的作用机制,总结证明中成药中含有改善糖耐量减低的各类有效成分。
Impaired glucose tolerance(IGT)is one of early phenomena of most diabetes mellitus type 2(T2DM).More and more studies have found that IGT is important intervention group to prevent type 2 diabetes.Although lifestyle intervention can reduce prognosis of IGT to type 2 diabetes,persistent lifestyle intervention is not easy to adhere to,and some high-risk IGT patients need intervention of drug treatment.At present,known hypoglycemic western drugs have great side effect and more restrictions on adverse reactions,patients prefer to Chinese patent medicine for treatment.Chinese patent medicine can achieve effect of enhancing effect and reducing toxicity through drug compatibility.The paper discusses pathogenesis of impaired glucose tolerance,explores action mechanism of some single substance drugs with higher frequency,summarizes and proves that Chinese patent drugs contain various effective ingredients to improve impaired glucose tolerance.
作者
李杰
彭波
LI Jie;PENG Bo(Clinical Medical College,Chengdu University of Traditional Chinese Medicine,Chengdu,Sichuan 610075;Chengdu University of Traditional Chinese Medicine Affiliated Hospital,Chengdu,Sichuan 610075)
出处
《智慧健康》
2023年第1期141-145,共5页
Smart Healthcare
基金
课题项目《中医药传承与创新“百千万”人才工程:全国老中医药专家学术经验继承项目》(项目编号:国中医药人教发[2017]29号)。
关键词
IGT
2型糖尿病
中成药
单味药
IGT
Mechanism of action
Chinese patent medicine
Single substance drug
